Interferon beta-1a (Avonex)
Sponsors
Biogen
Conditions
Multiple Sclerosis
Phase 4
Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
CompletedNCT00913666
Start: 2002-11-30End: 2004-11-30Updated: 2009-06-04
Open-Label Safety Extension Study of Avonex
CompletedNCT00915460
Start: 1999-09-30End: 2003-07-31Updated: 2009-06-08